{
  "item1": "individual's heart. vision transform patient care where patients diagnosed earlier, treated routine fashion, live longer, enjoy better quality life. future growth opportunities include offering solutions treating patients both valvular non-valvular structural heart disease, such heart failure, which natural progression disease many patients suffering aortic stenosis mitral tricuspid regurgitation. Patients undergoing treatment cardiovascular disease can treated number medical technologies, which designed address individual patient needs respect disease process, comorbidities, health status.",
  "item7": "RESILIA valve United States, Europe, Japan; partially offset by: foreign currency exchange rate fluctuations, which decreased net sales outside United States $13.6 million primarily due weakening Japanese yen against United States dollar, partially offset strengthening Euro against United States dollar. While global competitive position pricing remained stable during 2024, experienced some regional sales pressure reduction procedures certain hospital centers United States related variety factors including, but not limited to, resources priorities. January 2024, completed patient enrollment PROGRESS pivotal trial, studying treatment moderate patients, received CE Mark approval Edwards SAPIEN 3 Ultra RESILIA valve Europe. September 2024, received CE mark transcatheter pulmonary valve system adaptive prestent use management patients severe pulmonary regurgitation.",
  "item2": "leading global structural heart disease innovation company, driven passion improve patient lives. Through breakthrough technologies, world-class evidence, partnerships clinicians healthcare stakeholders, employees inspired patient-focused culture deliver life-changing innovations those who need them most. conduct operations worldwide managed following geographical regions: United States, Europe, Japan, Rest World. products categorized into following groups: Transcatheter Aortic Valve Replacement (“TAVR”), Transcatheter Mitral Tricuspid Therapies (“TMTT”), Surgical Structural Heart (“Surgical”)."
}